The Pathophysiology and Treatment of Osteoporosis

Clinical Therapeutics

Volumn 37, Issue 8, 2015, Pages 1837-1850

  Drake, Matthew T ^a   Clarke, Bart L ^a   Lewiecki, E Michael ^b  

^a Mayo Clinic College of Medicine   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

bisphosphonate; bone; bone mineral density; Key words aging; menopause; osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; ESTROGEN; FOLLITROPIN; IBANDRONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VITAMIN D; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

AGING; ANDROGEN DEFICIENCY; ARTICLE; BONE DENSITY; BONE MASS; BONE REMODELING; BONE STRENGTH; ESTROGEN DEFICIENCY; FEMALE; FOREARM FRACTURE; HIP FRACTURE; HUMAN; HYPERPARATHYROIDISM; MALE; MENOPAUSE; OSSIFICATION; OSTEOCLAST ACTIVITY; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; POSTMENOPAUSE; SPINE FRACTURE; TRABECULAR BONE; VITAMIN D DEFICIENCY; ADULT; DRUG EFFECTS; MIDDLE AGED; OSTEOPOROTIC FRACTURES; PHYSIOLOGY;

ADULT; AGING; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES;

EID: 84940719700     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2015.06.006     Document Type: Review

References (89)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy JAMA 285 2001 785 795
2. B.L. Riggs, S. Khosla, and L.J. Melton 3rd Sex steroids and the construction and conservation of the adult skeleton Endocr Rev 23 2002 279 302
3. B. Dawson-Hughes, A.C. Looker, A.N. Tosteson, and et al. The potential impact of the National Osteoporosis Foundation guidance on treatment eligibility in the USA: an update in NHANES 2005-2008 Osteoporos Int 23 2012 811 820
4. S.R. Cummings, and L.J. Melton Epidemiology and outcomes of osteoporotic fractures Lancet 359 2002 1761 1767
5. R. Burge, B. Dawson-Hughes, D.H. Solomon, and et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025 J Bone Miner Res 22 2007 465 475
6. B. Dawson-Hughes, A.N. Tosteson, L.J. Melton 3rd, et al. National Osteoporosis Goundation Guide Committee Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA Osteoporos Int 19 2008 449 458
7. B.L. Riggs, L.J. Melton 3rd, R.A. Robb, and et al. Population-based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites J Bone Miner Res 19 2004 1945 1954
8. S. Khosla, and B.L. Riggs Pathophysiology of age-related bone loss and osteoporosis Endocrinol Metab Clin North Am 34 2005 1015 1030
9. C.H. Turner Bone strength: current concepts Ann N Y Acad Sci 1068 2006 429 446
10. C. Cooper, and L.J. Melton 3rd Epidemiology of osteoporosis Trends Endocrinol Metab 3 1992 224 229
11. S. Khosla, E.J. Atkinson, L.J. Melton 3rd, and B.L. Riggs Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women: a population-based study J Clin Endocrinol Metab 82 1997 1522 1527
12. D.E. Hughes, A. Dai, J.C. Tiffee, and et al. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta Nat Med 2 1996 1132 1136
13. S.C. Manolagas Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis Endocr Rev 21 2000 115 137
14. P. Garnero, E. Sornay-Rendu, M.C. Chapuy, and P.D. Delmas Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis J Bone Miner Res 11 1996 337 349
15. J.C. Gallagher, M.M. Young, and B.E. Nordin Effects of artificial menopause on plasma and urine calcium and phosphate Clin Endocrinol 1 1972 57 64
16. C. Gennari, D. Agnusdei, P. Nardi, and R. Civitelli Estrogen preserves a normal intestinal responsiveness to 1,25-dihydroxyvitamin D3 in oophorectomized women J Clin Endocrinol Metab 71 1990 1288 1293
17. S. Khosla, L.J. Melton 3rd, and B.L. Riggs The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed? J Bone Miner Res 26 2011 441 451
18. W.R. McKane, S. Khosla, M.F. Burritt, and et al. Mechanism of renal calcium conservation with estrogen replacement therapy in women in early postmenopause - a clinical research center study J Clin Endocrinol Metab 80 1995 3458 3464
19. J.A. Cauley Estrogen and bone health in men and women Steroids 99 2015 11 15
20. G. Eghbali-Fatourechi, S. Khosla, A. Sanyal, and et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women J Clin Invest 111 2003 1221 1230
21. L.C. Hofbauer, S. Khosla, C.R. Dunstan, and et al. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells Endocrinology 140 1999 4367 4370
22. S. Tanaka, N. Takahashi, N. Udagawa, and et al. Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors J Clin Invest 91 1993 257 263
23. R.L. Jilka, G. Hangoc, G. Girasole, and et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6 Science 257 1992 88 91
24. P. Ammann, R. Rizzoli, J.P. Bonjour, and et al. Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency J Clin Invest 99 1997 1699 1703
25. H. Kawaguchi, C.C. Pilbeam, S.J. Vargas, and et al. Ovariectomy enhances and estrogen replacement inhibits the activity of bone marrow factors that stimulate prostaglandin production in cultured mouse calvariae J Clin Invest 96 1995 539 548
26. N. Charatcharoenwitthaya, S. Khosla, E.J. Atkinson, and et al. Effect of blockade of TNF-alpha and interleukin-1 action on bone resorption in early postmenopausal women J Bone Miner Res 22 2007 724 729
27. N.K. Shevde, A.C. Bendixen, K.M. Dienger, and J.W. Pike Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression Proc Natl Acad Sci U S A 97 2000 7829 7834
28. S. Srivastava, G. Toraldo, M.N. Weitzmann, and et al. Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation J Biol Chem 276 2001 8836 8840
29. U.I. Modder, J.A. Clowes, K. Hoey, and et al. Regulation of circulating sclerostin levels by sex steroids in women and in men J Bone Miner Res 26 2011 27 34
30. B.L. Clarke, and M.T. Drake Clinical utility of serum sclerostin measurements Bonekey Rep 2 2013 361
31. M.R. Sowers, M. Jannausch, D. McConnell, and et al. Hormone predictors of bone mineral density changes during the menopausal transition J Clin Endocrinol Metab 91 2006 1261 1267
32. P.R. Ebeling, L.M. Atley, J.R. Guthrie, and et al. Bone turnover markers and bone density across the menopausal transition J Clin Endocrinol Metab 81 1996 3366 3371
33. L. Sun, Y. Peng, A.C. Sharrow, and et al. FSH directly regulates bone mass Cell 125 2006 247 260
34. M.T. Drake, L.K. McCready, K.A. Hoey, and et al. Effects of suppression of follicle-stimulating hormone secretion on bone resorption markers in postmenopausal women J Clin Endocrinol Metab 95 2010 5063 5068
35. M.T. Drake, and S. Khosla Male osteoporosis Endocrinol Metab Clin North Am 41 2012 629 641
36. S. Khosla, L.J. Melton 3rd, E.J. Atkinson, and et al. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen J Clin Endocrinol Metab 83 1998 2266 2274
37. C.W. Slemenda, C. Longcope, L. Zhou, and et al. Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens J Clin Invest 100 1997 1755 1759
38. G.A. Greendale, S. Edelstein, and E. Barrett-Connor Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study J Bone Miner Res 12 1997 1833 1843
39. J.R. Center, T.V. Nguyen, P.N. Sambrook, and J.A. Eisman Hormonal and biochemical parameters in the determination of osteoporosis in elderly men J Clin Endocrinol Metab 84 1999 3626 3635
40. S. Amin, Y. Zhang, C.T. Sawin, and et al. Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham study Ann Intern Med 133 2000 951 963
41. S. Khosla, L.J. Melton 3rd, E.J. Atkinson, and W.M. 'oFallon Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men J Clin Endocrinol Metab 86 2001 3555 3561
42. S. Khosla, L.J. Melton 3rd, R.A. Robb, and et al. Relationship of volumetric BMD and structural parameters at different skeletal sites to sex steroid levels in men J Bone Miner Res 20 2005 730 740
43. A. Falahati-Nini, B.L. Riggs, E.J. Atkinson, and et al. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men J Clin Invest 106 2000 1553 1560
44. G.K. Wakley, H.D. Schutte Jr., K.S. Hannon, and R.T. Turner Androgen treatment prevents loss of cancellous bone in the orchidectomized rat J Bone Miner Res 6 1991 325 330
45. K.Y. Ho, W.S. Evans, R.M. Blizzard, and et al. Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations J Clin Endocrinol Metab 64 1987 51 58
46. A.E. Bennett, H.W. Wahner, B.L. Riggs, and R.L. Hintz Insulin-like growth factors I and II: aging and bone density in women J Clin Endocrinol Metab 59 1984 701 704
47. S. Boonen, S. Mohan, J. Dequeker, and et al. Down-regulation of the serum stimulatory components of the insulin-like growth factor (IGF) system (IGF-I, IGF-II, IGF binding protein [BP]-3, and IGFBP-5) in age-related (type II) femoral neck osteoporosis J Bone Miner Res 14 1999 2150 2158
48. S. Amin, B.L. Riggs, E.J. Atkinson, and et al. A potentially deleterious role of IGFBP-2 on bone density in aging men and women J Bone Miner Res 19 2004 1075 1083
49. P.J. Marie Bone cell senescence: mechanisms and perspectives J Bone Miner Res 29 2014 1311 1321
50. J.N. Farr, M.T. Drake, S. Amin, and et al. In vivo assessment of bone quality in postmenopausal women with type 2 diabetes J Bone Miner Res 29 2014 787 795
51. G.R. Emkey, and S. Epstein Secondary osteoporosis: pathophysiology & diagnosis Best Pract Res Clin Endocrinol Metab 28 2014 911 935
52. R. Rizzoli, J. Branco, M.L. Brandi, and et al. Management of osteoporosis of the oldest old Osteoporos Int 25 2014 2507 2529
53. G. Khastgir, J. Studd, N. Holland, and et al. Anabolic effect of estrogen replacement on bone in postmenopausal women with osteoporosis: histomorphometric evidence in a longitudinal study J Clin Endocrinol Metab 86 2001 289 295
54. G. Wells, P. Tugwell, B. Shea, et al. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women Endocr Rev 23 2002 529 539
55. D.J. Torgerson, and S.E. Bell-Syer Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials BMC Musculoskelet Disord 2 2001 7
56. J.A. Cauley, J. Robbins, Z. Chen, and et al. Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women trial JAMA 290 2003 1729 1738
57. J.E. Rossouw, G.L. Anderson, R.L. Prentice, and et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women controlled trial JAMA 288 2002 321 333
58. J.V. Pinkerton, and S. Thomas Use of SERMs for treatment in postmenopausal women J Steroid Biochem Mol Biol 142 2014 142 154
59. J.V. Pinkerton, J.A. Harvey, R. Lindsay, and et al. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial J Clin Endocrinol Metab 99 2014 E189 E198
60. M.T. Drake, and S.C. Cremers Bisphosphonate therapeutics in bone disease: the hard and soft data on osteoclast inhibition Mol Interv 10 2010 141 152
61. M.T. Drake, B.L. Clarke, and S. Khosla Bisphosphonates: mechanism of action and role in clinical practice Mayo Clin Proc 83 2008 1032 1045
62. J.E. Dunford, K. Thompson, F.P. Coxon, and et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates J Pharmacol Exp Ther 296 2001 235 242
63. K.L. Kavanagh, K. Guo, J.E. Dunford, and et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs Proc Natl Acad Sci U S A 103 2006 7829 7834
64. S.A. Khan, J.A. Kanis, S. Vasikaran, and et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis J Bone Miner Res 12 1997 1700 1707
65. D.M. Black, S.R. Cummings, D.B. Karpf, and et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group Lancet 348 1996 1535 1541
66. D.M. Black, A.V. Schwartz, K.E. Ensrud, et al. FLEX Research Group Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial JAMA 296 2006 2927 2938
67. A.V. Schwartz, D.C. Bauer, S.R. Cummings, et al. FLEX Research Group Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial J Bone Miner Res 25 2010 976 982
68. S.T. Harris, N.B. Watts, H.K. Genant, and et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group JAMA 282 1999 1344 1352
69. J. Reginster, H.W. Minne, O.H. Sorensen, and et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group Osteoporos Int 11 2000 83 91
70. P.D. Delmas, R.R. Recker, C.H. Chesnut 3rd, and et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study Osteoporos Int 15 2004 792 798
71. R. Recker, J.A. Stakkestad, C.H. Chesnut 3rd, and et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis Bone 34 2004 890 899
72. D.M. Black, P.D. Delmas, R. Eastell, and et al. HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 2007 1809 1822
73. K.A. Kennel, and M.T. Drake Adverse effects of bisphosphonates: implications for osteoporosis management Mayo Clin Proc 84 2009 632 637 quiz 638
74. A.A. Khan, A. Morrison, D.A. Hanley, and et al. International Task Force on Osteonecrosis of the Jaw. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus J Bone Miner Res 30 2015;3 23
75. E. Shane, D. Burr, B. Abrahamsen, and et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research J Bone Miner Res 29 2014 1 23
76. M. McClung Controversies in osteoporosis management: concerns about bisphosphonates and when are "drug holidays " required? Clin Obstet Gynecol 56 2013 743 748
77. S.R. Cummings, J. San Martin, M.R. McClung, and et al. FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis N Engl J Med 361 2009 756 765
78. H.G. Bone, R. Chapurlat, M.L. Brandi, and et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension J Clin Endocrinol Metab 98 2013 4483 4492
79. E.B. Andrews, A.W. Gilsenan, K. Midkiff, and et al. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years J Bone Miner Res 27 2012 2429 2437
80. R.M. Neer, C.D. Arnaud, J.R. Zanchetta, and et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 2001 1434 1441
81. R. Lindsay, J. Nieves, C. Formica, and et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis Lancet 350 1997 550 555
82. J.S. Finkelstein, J.J. Wyland, H. Lee, and R.M. Neer Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis J Clin Endocrinol Metab 95 2010 1838 1845
83. F. Cosman, E.F. Ericksen, C. Recknor, and et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis J Bone Miner Res 26 2011 503 511
84. J.N. Tsai, A.V. Uihlein, H. Lee, and et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial Lancet 382 2013 50 56
85. B.Z. Leder, J.N. Tsai, A.V. Uihlein, and et al. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial J Clin Endocrinol Metab 99 2014 1694 1700
86. N.B. Watts, R.A. Adler, J.P. Bilezikian, and et al. Endocrine Society. Osteoporosis in men: an Endocrine Society clinical practice guideline J Clin Endocrinol Metab 97 2012 1802 1822
87. M. Novinec, B. Lenarcic, and K. Cathepsin a unique collagenolytic cysteine peptidase Biol Chem 394 2013 1163 1179
88. B. Langdahl, N. Binkley, H. Bone, and et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study J Bone Miner Res 27 2012 2251 2258
89. M.R. McClung, A. Grauer, S. Boonen, and et al. Romosozumab in postmenopausal women with low bone mineral density N Engl J Med 370 2014 412 420